Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Lipid-functionalized Dextran Nanosystems to Overcome Multidrug Resistance in Cancer: A Pilot Study

Lipid-functionalized Dextran Nanosystems to Overcome Multidrug Resistance in Cancer: A Pilot Study Biocompatible dextran-based nanoparticles that are directly translatable to clinical medicine may lead to new potential therapeutics for reversing MDR in patients with cancer. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Orthopaedics and Related Research Wolters Kluwer Health

Lipid-functionalized Dextran Nanosystems to Overcome Multidrug Resistance in Cancer: A Pilot Study

Loading next page...
 
/lp/springer-journal/lipid-functionalized-dextran-nanosystems-to-overcome-multidrug-v2H79oUI7X

References (71)

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2012 by The Association of Bone and Joint Surgeons®
Subject
Medicine & Public Health; Orthopedics; Surgical Orthopedics; Medicine/Public Health, general; Surgery; Sports Medicine; Conservative Orthopedics
ISSN
0009-921X
eISSN
1528-1132
DOI
10.1007/s11999-012-2610-2
pmid
23011844
Publisher site
See Article on Publisher Site

Abstract

Biocompatible dextran-based nanoparticles that are directly translatable to clinical medicine may lead to new potential therapeutics for reversing MDR in patients with cancer.

Journal

Clinical Orthopaedics and Related ResearchWolters Kluwer Health

Published: Sep 21, 2012

There are no references for this article.